Iris de Nie

91 HISTOLOGICAL STUDY ON THE INFLUENCE OF PUBERTY SUPPRESSION AND HORMONAL TREATMENT ON DEVELOPING GERM CELLS 6 Table 1. Baseline characteristics at time of genital gender affirming surgery Total (n=214) Adolescent Tanner stage 2-3 (n=29) Adolescent Tanner stage 4-5 (n=49) Adult (n=136) Cessation of GAHT (n=19) Continuation of GAHT (n=10) Cessation of GAHT (n=35) Continuation of GAHT (n=14) Cessation of GAHT (n=62) Continuation of GAHT (n=74) Age (years) - Mean (SD) 29.6 (12.4) 19.0 (1.5) 19.6 (1.9) 19.7 (1.2) 19.3 (0.7) 34.5 (12.3) 36.2 (12.2) Alcohol Drinker % (n) Non-drinker % (n) Unknown - n 44% (82) 56% (106) 26 43% (6) 57% (8) 5 30% (3) 70% (7) 0 60% (18) 40% (12) 5 21% (3) 79% (11) 0 56% (26) 44% (20) 16 35% (26) 65% (48) 0 Smoking Smoker % (n) Non-smoker % (n) Unknown - n 7% (12) 93% (171) 31 0% 100% (15) 4 0% 100% (10) 0 8% (2) 92% (24) 9 0% 100% (14) 0 22% (10) 78% (34) 18 0% 100% 0 Cannabis use Yes % (n) No % (n) Unknown - n 3% (5) 97% (166) 43 0% 100% (15) 4 0% 100% (10) 0 4% (1) 96% (24) 10 7 (1) 93% (13) 0 6% (2) 94% (31) 29 1% (1) 99% (73) 0 BMI (kg/m 2 ) - Mean (SD) 23.1 (3.3) 22.0 (3.3) 23.2 (2.8) 21.6 (3.6) 20.9 (3.6) 23.9 (2.9) 23.8 (3.0) Mean duration of medical treatment (years)~ - (SD) 3.3 (2.0) 5.9 (1.4) 6.8 (1.3) 4.1 (1.8) 2.8 (0.6) 2.8 (1.9) 2.3 (1.2) Testosterone suppression Triptorelin injections % (n) Cyproterone acetate % (n) 36% (78) 64% (136) 100% (19) 0% 100% (10) 0% 100% (35) 0% 100% (14) 0% 0% 100% (62) 0% 100% (74) Estrogen supplementation Transdermal formulation % (n) Oral formulation % (n) 25% (54) 75% (160) 11% (2) 89% (17) 10% (1) 90% (9) 0% 100% (35) 0% 100% (14) 40% (25) 60% (37) 35% (26) 65% (48) Serum hormone levels before gGAS –Median (IQR)^ Testosterone (nmol/L) Estradiol (pmol/L) LH (U/L) FSH (U/L) 0.7 (0.5-1.0) 193 (120-307) 0.1 (0.1-0.3) 0.2 (0.1-0.5) 1.0 (0.8-1.0) 95 (43-332) 0.2 (0.1-0.4) 0.2 (0.1-0.5) 0.6 (0.5-0.8) 160 (141-392) 0.3 (0.2-0.5) 0.4 (0.4-0.5) 1.0 (0.6-1.2) 120 (82-220) 0.3 (0.2-0.4) 0.2 (0.1-0.5) 0.6 (0.5-1.1) 222 (100-281) 0.2 (0.2-0.4) - 0.7 (0.5-1.0) 219 (130-282) 0.1 (0.1-0.3) 0.3 (0.1-0.5) 0.5 (0.5-0.8) 237 (151-341) 0.1 (0.1-0.1) 0.8 (0.1-3.0) ~ including gonadotropin-releasing hormone agonist use, if applicable ^ data were available for 201 (testosterone and LH), 200 (estradiol), and 53 (FSH) transgender women, respectively.